(esophagus, liver, lung, ovarian, pancreatic, and stomach). Natera presented data from GALAXY arm of the CIRCULATE-Japan trial in stages II-IV CRC that showed Signatera status was predictive of overall survival, was predictive of benefit from adjuvant chemotherapy, was the most significant ...
Evaluation of dysphagia or odynophagia; Evaluation of esophageal reflux symptoms that are persistent or recurrent despite appropriate therapy (appropriate therapy consists of an 8 week trial of standard dose once daily PPI; in patients with partial response, the dose may be increased to twice daily)...
Although glycomics has already reached clinical practice in the case of glycoengineered therapeutic proteins or even a diagnostic test (Glyco Liver Profile, Helena Biosciences) [150], some obstacles have to be overcome if wide use of these methods is to be expected in the near future. These bar...